Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 1999

View Archived Issues

Rigel identifies cancer- and inflammation-related gene

Company Profile: Helicon Therapeutics

Coulter acquires therapeutic antibody from Pharma Pacific

Phase II ECOG trial of didemnin B in melanoma patients yields indeterminate results

Dimethaid commences new topical antifungal study

Company Profile: Kosan Biosciences

New treatment for ALS available for licensing from Cornell Research Foundation

Spotlight on protein farnesyltransferase inhibitors

Medeva reviews product pipeline

LY-333531 reduces leukocyte accumulation in retinal microcirculation of diabetic rats

TerraGen establishes second collaboration with Schering-Plough

Introgen Therapeutics commences phase I trial of i.v. p53 gene therapy

New class of triterpene immunosuppressants described by Merck

Merck presents integrin antagonists with cell adhesion-inhibitory activity

Hematopoietic agents in development at Toray

Dual TxA2 and PGD2 antagonists from Shionogi

Benzenes with hypoglycemic and hypolipidemic effects in the Ono pipeline

Antiinflammatory thiadiazole amides act by inhibiting beta2 integrins

BASF discloses serotonergic agents for depression

New carbazole from Kyowa Hakko effective against chemotherapy-induced thrombocytopenia

Potential new use for diphenhydramine in uveitis

SKK-60060: new selectin inhibitor effective in animal model of retinal ischemia-reperfusion injury

Health Canada approves Cosopt glaucoma treatment

First European launch for Tanatril

Another European market introduction announced for emedastine

Versicor licenses antifungal compound from Lilly

Kinase inhibitor provides neuroprotection in focal cerebral ischemia

GDNF gene therapy approach to cerebrovascular disorders proven effective

Chiron begins first clinical trial of in vivo gene therapy for hemophilia

Inflazyme initiates phase I clinical trials with IPL-576092

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...